

Kevin J Anstrom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/694711/publications.pdf>

Version: 2024-02-01

67
papers

4,499
citations

126907

33
h-index

106344

65
g-index

69
all docs

69
docs citations

69
times ranked

6130
citing authors

#	ARTICLE	IF	CITATIONS
1	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	7.1	16
2	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	10
3	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 14-23.	5.6	32
4	Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1841.	7.4	43
5	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <scp>VICTORIA</scp> (<scp>Vericiguat</scp> Global Study in) Tj ETQq1 1 0.784314 rgB34Overlo	7.4	14
6	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	6.1	53
7	Antimicrobial Therapy and Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosisâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1071.	7.4	0
8	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2302-2309.e6.	0.8	40
9	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	7.4	170
10	Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107616.	2.3	3
11	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	27.0	753
12	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy â€” the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. <i>Respiratory Research</i> , 2020, 21, 68.	3.6	17
13	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. <i>JAMA Cardiology</i> , 2020, 5, 757.	6.1	74
14	Real-World Integration of a Sepsis Deep Learning Technology Into Routine Clinical Care: Implementation Study. <i>JMIR Medical Informatics</i> , 2020, 8, e15182.	2.6	86
15	Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleepÂapnea. <i>Heart Rhythm</i> , 2019, 16, 91-97.	0.7	20
16	NT-proBNP Goal Achievement IsÂAssociated With Significant ReverseÂRemodeling and Improved Clinical Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 158-168.	4.1	65
17	Predictive ability of perioperative atrial fibrillation risk indices in cardiac surgery patients: a retrospective cohort study. <i>Canadian Journal of Anaesthesia</i> , 2018, 65, 786-796.	1.6	12
18	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	7.4	187

#	ARTICLE	IF	CITATIONS
19	Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. <i>American Heart Journal</i> , 2018, 204, 202-204.	2.7	14
20	Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2304-2313.	2.8	14
21	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	3.9	45
22	Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 750.	6.1	50
23	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	6.1	18
24	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017, 376, 2032-2042.	27.0	225
25	Palliative Care in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 331-341.	2.8	425
26	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	1.8	13
27	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. <i>American Heart Journal</i> , 2016, 177, 33-41.	2.7	13
28	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	38
29	Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease. <i>Circulation</i> , 2016, 133, 1995-2007.	1.6	35
30	Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	9
31	Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	25
32	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	4.1	30
33	Safety and clinical effectiveness of drug-eluting stents for saphenous vein graft intervention in older individuals: Results from the medicare-linked National Cardiovascular Data Registry Cath PCI Registry (2005-2009). <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 43-49.	1.7	16
34	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	46
35	Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	7
36	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016, 182, 62-71.	2.7	23

#	ARTICLE	IF	CITATIONS
37	Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2016, 1, 655.	6.1	19
38	Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	19
39	Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. <i>Circulation</i> , 2016, 133, 39-47.	1.6	58
40	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	1.6	47
41	Assessing Quality of Life and Medical Care in Chronic Angina: An Internet Survey. <i>Interactive Journal of Medical Research</i> , 2016, 5, e12.	1.4	3
42	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 741-748.	3.9	235
43	Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001403.	3.9	47
44	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. <i>Journal of the American Heart Association</i> , 2015, 4, e002061.	3.7	14
45	In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 499-508.	1.0	68
46	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. <i>Journal of the American College of Cardiology</i> , 2015, 65, 465-476.	2.8	30
47	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	4.1	30
48	Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Trial. <i>Circulation: Heart Failure</i> , 2015, 8, 221-228.	3.9	31
49	Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 145-151.	4.8	14
50	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	3.9	16
51	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 388-396.	10.7	69
52	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
53	Examination of the Treatment Selection Process in a Multicenter Observational Study. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 764-769.	2.2	0
54	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	7.4	35

#	ARTICLE	IF	CITATIONS
55	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. <i>Stroke</i> , 2014, 45, 3243-3250.	2.0	35
56	GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 673-679.	3.9	41
57	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. <i>American Heart Journal</i> , 2014, 167, 796-803.e1.	2.7	104
58	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-799.	4.8	45
59	Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2014, 114, 716-722.	1.6	9
60	Rationale and Design of the GUIDE-IT Study. <i>JACC: Heart Failure</i> , 2014, 2, 457-465.	4.1	106
61	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2014, 146, 1256-1262.	0.8	28
62	Percutaneous Coronary Intervention and Drug-Eluting Stent Use Among Patients ≥ 85 Years of Age in the United States. <i>Journal of the American College of Cardiology</i> , 2012, 59, 105-112.	2.8	40
63	Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1044-1048.	5.6	209
64	A Generalized Estimator of the Attributable Benefit of an Optimal Treatment Regime. <i>Biometrics</i> , 2010, 66, 512-522.	1.4	31
65	Clinical Effectiveness of Coronary Stents in Elderly Persons. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1629-1641.	2.8	135
66	Long-term Clinical Outcomes Following Coronary Stenting. <i>Archives of Internal Medicine</i> , 2008, 168, 1647.	3.8	14
67	Long-term survival estimates for imatinib versus interferon- γ plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2004, 101, 2584-2592.	4.1	35